Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
03 8월 2022 - 5:10AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, announced today that it filed a lawsuit against
Foresight Diagnostics Inc. for infringement of Personalis’ U.S.
Patent Nos. 10,450,611, 11,299,783, and 11,384,394. These patents
are part of Personalis’ intellectual property portfolio in the
field of whole genome-enabled, tumor-informed molecular residual
disease (MRD) testing.
Personalis’ patent portfolio protects its pioneering work in
whole genome sequencing to identify mutations that indicate the
continued presence or recurrence of cancer with part-per-million
sensitivity. Personalis is seeking both injunctive relief and
monetary damages based upon Foresight’s infringement of these
patents.
“Personalis has been active in whole human genome sequencing
from very early on. By 2013, when we first began filing the
applications that led to the patents we are asserting against
Foresight, Personalis had already received customer orders to
sequence and analyze over 1,000 human genomes and had realized the
power of utilizing whole genome sequencing alongside our advanced
targeted sequencing methods,” said Personalis CEO, John West.
Personalis launched its ultra-sensitive MRD solution, NeXT
Personal™, in late 2021. NeXT Personal leverages many elements of
the asserted patents, including the use of whole genome sequencing
to identify up to 1,800 variants that are specific to a patient’s
cancer, thereby achieving superior signal-to-noise in the detection
of ctDNA in plasma samples. NeXT Personal is purpose-built to
accurately detect MRD in patient samples with low overall ctDNA,
which is particularly important for cancers that have low shedding
or low mutational burden, such as breast and prostate cancers, or
soon after resection.
“Personalis has invested hundreds of millions of dollars in
research and development across a broad array of disciplines for
over a decade, and we stand firm in our resolve to protect that
investment and our leadership position in the field. NeXT Personal
is our most recent product leveraging our pioneering work. We
believe that it represents the most sensitive MRD approach for
solid tumors and can be transformational in cancer, detecting
residual disease and recurrence, and in actively fighting cancer
after recurrence has been detected,” Mr. West added.
About NeXT Personal
NeXT Personal is a next-generation, tumor-informed liquid biopsy
assay designed to detect and quantify MRD and recurrence in
patients previously diagnosed with cancer. The assay is designed to
deliver industry-leading MRD sensitivity down to the 1
part-per-million range, an approximately 10- to 100-fold
improvement over other available technologies. It leverages whole
genome sequencing of a patient’s tumor to identify up to 1,800
specially selected somatic variants that are subsequently used to
create a personalized liquid biopsy panel for each patient. This
may enable earlier detection across a broader variety of cancers
and stages, including typically challenging early-stage, low
mutational burden, and low-shedding cancers. NeXT Personal is also
designed to simultaneously detect and quantify clinically relevant
mutations in ctDNA that may be used in the future to help guide
therapy when cancer is detected. These include known targetable
cancer mutations, drug resistance mutations, and new variants that
can emerge and change over time, especially under therapeutic
pressure.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics,
enabling the next generation of precision cancer therapies and
diagnostics. The Personalis NeXT Platform® is designed to adapt to
the complex and evolving understanding of cancer, providing its
biopharmaceutical customers and clinicians with information on all
of the approximately 20,000 human genes, together with the immune
system, from a single sample. To enable cancer sequencing,
Personalis' Clinical Laboratory was built with a focus on clinical
accuracy, quality, big data, scale, and efficiency. The laboratory
is GxP-aligned as well as Clinical Laboratory Improvement
Amendments of 1988-certified and College of American
Pathologists-accredited. For more information, visit the Personalis
website and follow Personalis on LinkedIn and Twitter.
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the NeXT or NeXT Personal platforms, Personalis’ business
opportunities, leadership, plans, or expectations, legal
proceedings to enforce patents, the presumed validity or
enforceability of the company’s patents or other intellectual
property rights, the potential issuance of additional patents from
the company’s pending or future patent applications, or other
future events. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from any anticipated results or expectations expressed or implied
by such statements. Factors that could materially affect actual
results can be found in Personalis’ filings with the U.S.
Securities and Exchange Commission, including Personalis’ most
recent reports on Forms 8-K, 10-K and 10-Q, the company’s
registration statement on Form S-3 filed on December 30, 2020, and
the company’s prospectus supplement filed on January 3, 2022, and
include those listed under the caption “Risk Factors.” Personalis
disclaims any obligation to update such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220802006051/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Temple
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024